Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Ulcerative colitis, Crohn's disease, rheumatoid arthritis. Clinical selection for Sulphasalazine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Acute attack: Adult; 1000-2000mg QID, Children over 2 years; 40-60mg/kg daily- until remission occurs. Maintenance: Adult; 500mg QID, Children over 2 years; 20-30mg/kg daily.
Adverse reactions vary by agent. Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes). Report suspected ADRs via national pharmacovigilance channels.
Store as labelled. Keep out of reach of children.